The survival history of 259 patients with Stage I cutaneous malignant melanoma who were at risk for developing regional nodal metastases (Stage 11) were studied. Eighty-seven of 377 Stage I patients (23%) developed regional nodal metastases (Stage IIB) with 40% 5-year survival. Fifty patients had regional nodal metastases at presentation, with or without a known primary (Stages IIA or I & -. , respectively), with a 42% 5-year survival. A step-down multivariate analysis using the Cox regression model revealed four risk factors as being highly significant for predicting a more favorable survival outcome: (1) thinner Breslow thickness (P = O.OOOl), (2) pathologic Stage I disease (P = 0.004), (3) no clinical ulceration (P = 0.0004), and (4) being a woman younger than 50 years of age (P = 0.029). These results are discussed in reference to other series.
metastases, and improve the disease-free interval and/or survival. In patients with a worse prognosis and high probability of distant metastases (>4.00 mm), a less aggressive regional approach may not be indicated.
A multivariate analysis of 11 prognostic variables in 259 Stage I melanoma patients at risk for developing Stage I1 disease revealed the following four risk factors as significant for predicting a more favorable outcome: (1) thinner Breslow thickness ( P = 0.0001), ( 2 ) pathologic Stage I disease ( P = 0.004), (3) no clinical ulceration ( P = 0.004), and (4) a woman younger than 50 years of age ( P = 0.029).
Patients and Methods

Patient Population
From January 1, 1973 to April 1, 1984, 524 patients with malignant melanoma were followed at the Arizona Cancer Center. Clinical history and records were compiled from the date of original diagnosis (date of histologically proven melanoma) to the last date of follow-up or death. IUCC classification staging criteria were used.
Of the 524 patients, 440 patients had Stage I and 54 patients had Stage I1 disease at diagnosis. Thirty-eight patients with Stage I noncutaneous melanoma were excluded from analysis. Twenty-eight patients who did not have a wide local excision within 2 months were also excluded, leaving 374 patients who had adequate surgical therapy for Stage I cutaneous melanoma. To evaluate prognostic factors that could predict which patients with Stage I melanoma developed local nodal metastases (Stage 11), 115 patients who progressed directly from Stage I to Stage 111 (distant metastatic disease) were also excluded.
The history of disease recurrence of the 259 evaluable patients diagnosed as Stage I is summarized in Figure 1 . The median follow-up was 30 months. Of the 259 evaluable patients, 158 (6 1 %) had their initial diagnostic slides reviewed by one of the authors (B.P.) for the level of penetration according to Clark et al.,' depth of penetration in millimeters, according to Breslow,' histologic type, and the presence or absence of ulceration. The natural history of the patients who developed Stage I1 disease is also summarized in Figure 1 . Eighty-seven (34%) of the 259 patients developed pathologic Stage I1 disease (delayed nodal metastases, Stage IIB) at a median follow-up of 19 months, whereas 172 patients (median follow-up of 33 months) remained free of disease.
Of the 54 patients with Stage I1 disease at diagnosis (initial Stage I1 disease [Stage IIA and IIc]), two patients with noncutaneous melanoma and two patients who did not have a regional lymph node dissection within 2 months of their diagnosis were excluded from subsequent analysis, leaving 50 evaluable patients. Their median follow-up was 25 months.
Thus, 87 (64%) of the evaluable patients with Stage I1 disease progressed from Stage I melanoma and 50 (36%) initially had Stage I1 disease. All patients with nodal disease underwent a surgical lymphadenectomy and were shown to have metastatic involvement of regional lymph nodes confirmed by a pathologist. Removal of the primary tumor by a wide local excision was done if the patients also had a primary lesion.
Statistical Analysis
The Kaplan and Meier" method was used for statistical estimation of the survival-type curves reflecting the time from Stage I diagnosis to the last date of contact or death. Methods used to compare survival-type curves were the generalized Wilcoxon method of Gehan," the log-rank method of Mantel, l9 and the generalized Kruskal-Wallis method of Breslow.*' Multivariate analysis of prognostic factors for regional recurrence after Stage I disease used the 6X proportional hazard model.2' t Log-rank.
Results
Natural History
Of the 137 total patients with Stage I1 disease, 54 (39%) had no evidence of disease (NED) after a median followup of 27 months. Eighty-three (6 1 %) progressed to Stage I11 disease, and of those, five (6%) were alive with Stage I11 disease and 78 (94%) had died from Stage 111 disease, with a median time of 19 months. The overall 5-year survival was 44%.
Eighty-seven patients (63%) developed Stage I1 disease subsequent to documented antecedent Stage I melanoma (delayed nodal metastases or Stage IIB). Thirty-three of those (38%) were alive without evidence of melanoma after a median time of 28 months. Fifty-four (62%) had progressed to Stage I11 disease after a median time of only 10 months; two (4%) of those were alive, and 52 (96%) had died with a median time of 17 months. Their 5-year survival was 40%.
Fifty patients (36%) developed Stage I1 disease, de novo, i.e., without an antecedent cutaneous lesion. Of these, 36 had synchronous nodal metastases (Stage IIA) and 14 had nodal metastases without a known primary (Stage IIc). Of these 50 patients, 2 1 (42%) were free of disease after a median follow-up of 27 months, three (6%) were alive with Stage I11 disease, and 26 (52%) had died of Stage I11 disease, after a median time of 18 months. The 5-year survival of the 36 Stage IIA patients was 42%. Of these, 13 (36%) were NED after a median follow-up of 27 months, two (6%) were alive with Stage I11 disease, and 2 1 (58%) had died of Stage I11 disease, with a median time of 17 months.
The 5-year overall survival of the 14 Stage IIc patients was 64%. Eight patients (57%) were alive with no evidence of melanoma. After a median follow-up of 30 months, one patient (7%) was alive with Stage I11 disease. Five patients (36%) had died of Stage I11 disease after a median follow-up of 2 1 months.
When comparing the remission rates and 5-year survival rates of the various Stage I1 groups of patients, there were no statistically significant differences.
Predicting the Development of Nodal Metastases
Results from a univariate analysis of eight clinical and four pathologic prognostic factors are shown in Table 1 . The nine factors that predicted a greater median time to occurrence of nodal metastases were as follows: no clinical ulceration; an age/sex interaction, with young women doing much better than men or older women; thinner Breslow thickness; shallower Clark's level; superficial spreading primary type, no pathologic ulceration; female gender; age younger than 50 years; and a negative lymph node dissection revealing no nodal disease (pathologic Stage I). A family history of melanoma was of borderline significance (P = 0.06). The site of the primary and the location of the primary at a BANS (upper back, posterior arm, posterior neck, or posterior scalp)13 versus non-BANS site was not prognostic.
The results of multivariate analysis using a Cox proportional hazard model of the 1 1 prognostic variables are shown in Table 2 . Highly significant for predicting a more favorable outcome (less risk for developing nodal metastases) were a thinner Breslow thickness ( P = 0.0001), negative lymph node dissection (pathologic Stage I, P As demonstrated in the companion paper,4' for 197 patients with known Breslow thickness measurements, the regional nodal metastases incidences at 5 years were 12%, 16%, 30%, and 72%, respectively, for the 50.75 mm, 0.76-1.50 mm, 1.51-3.99 mm, and 24.00 mm subgroups. Patients who had a prophylactic lymph node dissection (PLND) had an incidence of 22% versus 32% for patients who had a wide local excision (WLE) alone. Because the Cox model predicted that there was statistically significant prognostic value in patients undergoing a PLND and staged as pathologic Stage I, patients were analyzed by Breslow subgroups to determine where the benefit existed. There was a low frequency of developing regional nodal metastases within 5 years in patients with Breslow thicknesses 50.75 mm or 0.76 to 1.50 mm. Within these two subgroups, there were no statistically significant differences between patients who had a WLE and those who had a WLE + PLND, with P = 0.27 and P = 0.65, respectively (Fig. 2) . However, there was a highly significant difference in the subgroup of patients with lesions 1.5 1 to 3.99 mm thick. Those who had a WLE + PLND developed regional nodal metastases in 17% of cases compared to 46% who had a WLE alone (P = 0.012). There was no statistical difference in the regional nodal metastasis frequency in the 24.00 mm subgroup (P = 0.10).
For patients with no clinical ulceration of the primary lesion, the incidence of developing Stage I1 disease was 24% compared to 48% in patients with clinical ulceration. The age/sex interaction also revealed significant differences, with young women having the most favorable prognosis; only 1% developed Stage I1 disease, whereas older women or men had the least favorable prognosis and 35% developed Stage I1 disease. The incidence of Stage I1 disease for patients with superficial spreading melanoma was 18% versus 39% for patients with other primary types. Our univariate analysis showed that nine prognostic factors were important and one factor was marginally significant in predicting Stage I1 disease (Table 1) . Four factors were highly significant and one factor marginally significant after multivariate analysis (Table 2) . A thinner Breslow thickness was significant both on univariate (P < 0.001) and multivariate analysis (P = 0.0001) and was the most important prognostic factor. A thinner Breslow thickness has been shown to predict both a better survival after Stage I disease, as well as to predict a lower frequency of nodal metastases using either u n i~a r i a t e ,~-~-~.~~?
Pathologic stage (as determined by a PLND) was the second most important prognostic factor and was highly significant on both univariate (P < 0.00 1) and multivariate (P = 0.002) analyses. Pathologic Stage I patients have no lymph node involvement at the time of surgery, whereas clinical Stage I patients have an increased risk of clinically undetectable but pathologically proven nodal metastases as the thickness of their primary increases.3-8,15,24,28-30,35,41 Thus, a patient with clinical Stage I disease has a poorer prognosis than a patient with pathologic Stage I disease. As shown in Figure 2 , patients with a primary lesion 1.5 1 to 3.99 mm thick had a significantly lower frequency of regional nodal metastases at 5 years (1 7% versus 46%) if they underwent a PLND and were confirmed as having pathologic Stage I disease (P = 0.0 12). These results support the recommendations of Balch et al." that patients with lesions 1.50 to 3.99 mm thick should undergo a PLND. Balch et aL3' did not comment on the development of Stage I1 disease after a PLND. However, a 46% increase in 5-year survival (from 37% to 83%) was noted in the subgroup of patients with lesions with Breslow thickness of 1.5 1 to 3.99 mm. Our multivariate analysis confirmed the better prognosis of Stage I patients undergoing a PLND (P = 0.0 1 9).41 Patients who were upstaged to pathologic Stage IIA had no differences in 5-year diseasefree survival, frequency to developing distant metastases, or overall 5-year survival when compared to those with delayed nodal metastases (Stage IIB). Therefore, patients with lesions 1.5 1 to 3.99 mm in thickness that underwent a PLND had a significantly lower frequency of developing nodal metastases if no nodal metastases were present at the time of surgery. However, if delayed nodal metastases did occur, these Stage IIB patients had the same 5-year survival from the time of nodal metastases development and the same frequency of developing distant metastases as did Stage IIA patients (once nodal metastases occurred, Stage IIA and IIB patients acted similarly).
The overall incidence of developing regional nodal metastases according to Breslow thickness was as follows: 50.75 mm = 11%, 0.76 to 1.50 mm = 18%, 1.51 to 3.99 mm = 34%, and 24.00 mm = 67%. The 11% incidence of Stage I1 disease at 5 years in patients with 50.75 mm lesions is high compared to the results of Balch et ~1 .~' and Breslow4 (O%), but is similar to that of Cohen et al. 24 (9%). Veronesi' reported a 5-year death rate of 5% in patients with lesions 50.75 mm. Our 18% incidence of Stage I1 disease in the 0.76 to 1.50 mm subgroup is similar to the 23% to 33% reported by Balch et ~1 . ~~ and Bre~low.~ The 0.76 to 1.50 mm subgroup has an intermediate prognosis between the 50.75 mm and 1.51 to 3.99 mm subgroups, as has been confirmed by Bre~low,~ Veronesi,' and Balch et ~1 .~' The 34% incidence of Stage I1 disease in the 1.5 1 to 3.99 mm subgroup was slightly lower than the 57% incidence seen at 3 years by Balch et The 67% incidence of Stage I1 disease of the 24.00 mm subgroup is consistent with the 65% reported by others and the 38% 5-year survival reported by Veronesi.' Thus, the subgroup of patients with 1.5 1 to 3.99 mm thick lesions tend to be at high risk for nodal metastases and may benefit from a PLND.
Absence of clinical ulceration was highly significant both on univariate (P < 0.001) and multivariate analysis (P = 0.004). Although pathologic ulceration was also highly significant on univariate analysis (P < 0.001), it was not significant (P > 0.10) on multivariate analysis after considering the significance of clinical ulceration, Breslow thickness, and primary type (increased incidence in nodular melanomas). Ulceration has been shown to be an independent (P < 0.005 and P = 0.0 1, respectively). An age/sex interaction was highly significant on univariate (P < 0.001) analysis and remained significant (P = 0.029) on multivariate analysis, and replaced age and sex as prognostic factors. Younger patients are reported to have an improved survival in Stage I disea~e.~.~.~'.~' Wo men have also had an improved survival in Stage I disease on both and multivariate' 1,14. 41 analyses. An age/sex interaction with improved survival for young women has been previously reported in Stage I patients by Davis et a1." and Meyskens et ~1 .~' This interaction was noted to replace both age and sex as prognostic factors in predicting nodal metastases on multivariate analysis. There was a markedly better prognosis for young women and a poorer prognosis for young men followed by older women; prognosis was poorest for older men.
A patient with a superficial spreading melanoma had less risk of developing Stage I1 disease than did a patient with another type of primary (nodular or aeral) on univariate analysis P < 0.00 1). Even though there was a significance of P = 0.039 on multivariate analysis, the type of primary could be removed from the Cox model without significantly altering the model. The type of primary was therefore considered to have marginal significance. Previous multivariate analyses in Stage I patients have also failed to show that the type of primary has had any progAlthough Clark's level was highly significant on univariate analysis (P < 0.00 l), it was not significant on multivariate analysis because its prognostic importance was replaced by the Breslow thickness. This finding has also been documented in Stage I patients by others.4*5.14,29.40.4' A family history of melanoma showed a marginal significance on univariate analysis. Although family history of melanoma was excluded from multivariate analysis because of its uncommon occurrence, many studies support its irnp~rtance.~~-~' Before the dysplastic nevus syndrome had been described, patients with multiple primaries had been shown to have a better prognosis independent of the thickness of the l e~i o n .~
The natural history of the dysplastic nevus syndrome and of patients with multiple primaries is currently under clinical
The primary site did not have significant prognostic importance on both univariate and multivariate analysis. Although Stage I patients with extremity lesions have a better prognosis than do patients with head, trunk, hand, or foot lesions on univariate analysis,4. Our results are similar in that the thickness of the lesion and sex of the patient were highly significant. However, they found age not to be prognostic, and no age/sex interaction was analyzed. A major difference in their study is the absence of any prognostic significance on univariate analysis of the cell type, Clark levels, or pathologic versus clinical stage of patients. We cannot comment on the prognostic significance of tumor elevation, mitotic activity, pleomorphism, or host reaction because this was not addressed in our study. However, Veronesi et al. l4 reported that these variables were not important in predicting survival of Stage I patients on multivariate analysis.
Only 87 of 374 patients (23%) with Stage I melanoma who progressed to pathologic Stage I1 melanoma were at risk for developing regional metastases. However, it is important to predict which patients are at highest risk for Stage I1 progression so that new treatments may be developed to prevent recurrence. The eventual progression of 6 1 % of these patients to Stage I11 disease and a short survival underscores this importance. Even if local nodal metastases occur in patients with melanoma (Stage 11), a relatively high proportion of patients (40%) remained free of disease after undergoing a lymph node dissection.
